Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: a nationwide population-based study from the Netherlands

Small cell lung cancer (SCLC) accounts for approximately 12% of all lung cancer diagnoses worldwide and is often ( ∼70%) metastasized at first presentation [1]. Almost all patients without distant metastases are diagnosed with locoregionally advanced disease [2]. Historically, SCLC was classified either as limited (disease confined to one hemithorax and regional lymph nodes that can be encompassed in the same radiation portal as the primary tumor) or extensive disease (the remainder). Limited disease roughly translates into the potentially curable TNM stages I-III, whereas extensive disease translates into stage IV [3].

Source: Lung Cancer - October 27, 2021 Category: Cancer & Oncology Authors: Jelle Evers, Lizza E.L. Hendriks, Katrien De Jaeger, Robin Wijsman, Dirk De Ruysscher, Chris Terhaard, Maurice van der Sangen, Sabine Siesling, Henk Struikmans, Mieke J. Aarts Source Type: research